CEL SCI Return On Assets Over Time
| CVM Stock | USD 0.60 0.10 14.29% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out CEL SCI Performance and CEL SCI Correlation. CEL |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CEL SCI. If investors know CEL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CEL SCI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.52) | Revenue Per Share 0.001 | Quarterly Revenue Growth (0.63) | Return On Assets (0.61) | Return On Equity (2.50) |
The market value of CEL SCI Corp is measured differently than its book value, which is the value of CEL that is recorded on the company's balance sheet. Investors also form their own opinion of CEL SCI's value that differs from its market value or its book value, called intrinsic value, which is CEL SCI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CEL SCI's market value can be influenced by many factors that don't directly affect CEL SCI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CEL SCI's value and its price as these two are different measures arrived at by different means. Investors typically determine if CEL SCI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CEL SCI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Return On Assets Analysis
Compare CEL SCI Corp and related stocks such as CTi Biopharma Corp, Agenus Inc, and Aeterna Zentaris Return On Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AGEN | (0.3232) | (1.1751) | (0.3266) | (0.8633) | (0.5701) | (0.3628) | (0.809) | (0.872) | (1.1708) | (0.9601) | (1.1194) | (0.2032) | (0.6565) | (0.7829) | (0.82) |
| CYCC | (0.4544) | (0.5863) | (0.6813) | (0.2858) | (0.6597) | (0.5791) | (0.5997) | (0.2873) | (0.3677) | (0.5114) | (0.2295) | (0.4435) | (0.7708) | (2.5616) | (2.43) |
| BCRX | (0.5391) | (0.6927) | (0.6804) | (0.6161) | (0.3302) | (0.3454) | (0.6138) | (0.369) | (0.6895) | (0.685) | (0.5873) | (0.313) | (0.4493) | (0.4382) | (0.46) |
CEL SCI Corp and related stocks such as CTi Biopharma Corp, Agenus Inc, and Aeterna Zentaris Return On Assets description
A profitability ratio that indicates the percentage of profit a company earns in relation to its overall resources. It is calculated by dividing net income by total assets.My Equities
My Current Equities and Potential Positions
| CEL SCI Corp | CVM |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Virginia; U.S.A |
| Exchange | NYSE MKT Exchange |
USD 0.6
Check out CEL SCI Performance and CEL SCI Correlation. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
CEL SCI technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.